Medical sciences (Basel, Switzerland) · 2026
An Exploratory Study on the Interrelation of Breast Cancer Molecular Phenotypes with Breast Cancer-Associated Adipose Tissues (BCAATs), Neoadjuvant, and Adjuvant Therapies: A Focus on Prognosis and Survival.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pasca Fenesan Mihaela Maria, Bogdan Razvan George, Cosma Andrei Alexandru, Vornicu Vlad, Melnic Eugen, Radu Diana Veronica, Baran Patricia, Crainiceanu Zorin, Heredea Rodica Elena, Cernetchi Olga, Cimpean Anca Maria
Аннотация
BACKGROUND/AIM: We previously described four distinct breast cancer (BC)-associated adipose tissue (BCAAT) subtypes that have a significant impact on survival. In this exploratory study, we aimed to determine whether these BCAAT subtypes exhibit significant correlations with neoadjuvant and adjuvant therapies and BC molecular subtypes.
METHODS: Four BCAAT subtypes previously identified as fibroblast-rich (FRich_BCAAT), myofibroblast-rich (MyoFRich_BCAAT), vascular-rich (VRich_BCAAT), and mixed vascular- and inflammation-rich (VIRich_BCAAT) were analyzed according to their distribution in BC molecular subtypes, as well as in relation to neoadjuvant therapy and survival.
RESULTS: Triple-negative BC and Luminal B (LB) BC are related to VRich and VIRich BCAAT subtypes and were affected by Epirubicin/Cyclophosphamide (EC)+ paclitaxel (PTX) therapy, which significantly enhanced overall survival (OS) and disease-free survival (DFS). For the Luminal A (LA) BC subtype, EC + docetaxel (DTX) had significant impact on survival independent of BCAAT subtype.
CONCLUSIONS: BCAAT subtypes strongly influenced neoadjuvant therapy response and survival depending on BC molecular subtype.
METHODS: Four BCAAT subtypes previously identified as fibroblast-rich (FRich_BCAAT), myofibroblast-rich (MyoFRich_BCAAT), vascular-rich (VRich_BCAAT), and mixed vascular- and inflammation-rich (VIRich_BCAAT) were analyzed according to their distribution in BC molecular subtypes, as well as in relation to neoadjuvant therapy and survival.
RESULTS: Triple-negative BC and Luminal B (LB) BC are related to VRich and VIRich BCAAT subtypes and were affected by Epirubicin/Cyclophosphamide (EC)+ paclitaxel (PTX) therapy, which significantly enhanced overall survival (OS) and disease-free survival (DFS). For the Luminal A (LA) BC subtype, EC + docetaxel (DTX) had significant impact on survival independent of BCAAT subtype.
CONCLUSIONS: BCAAT subtypes strongly influenced neoadjuvant therapy response and survival depending on BC molecular subtype.